Pacer Advisors Inc. Sells 913,713 Shares of BioMarin Pharmaceutical Inc. $BMRN

Key Points

• Pacer Advisors cut its BioMarin stake by 97.5%. The fund sold 913,713 shares during the first quarter, retaining 23,643 shares valued at approximately $1.34 million.
• BioMarin reported stronger-than-expected quarterly results. Earnings came in at $1.20 per share versus the $0.95 consensus, while revenue rose 20% year over year to $989.7 million.
• Institutional ownership remains very high at 98.71%. Analysts maintain a “Moderate Buy” consensus with an average price target of $87.86, although the company faces clinical-development risk after discontinuing a $270 million rare-disease asset.

Pacer Advisors Inc. lowered its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 97.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,643 shares of the biotechnology company's stock after selling 913,713 shares during the quarter. Pacer Advisors Inc.'s holdings in BioMarin Pharmaceutical were worth $1,336,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of BMRN. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at approximately $447,572,000. Vestal Point Capital LP grew its stake in shares of BioMarin Pharmaceutical by 261.4% in the fourth quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company's stock worth $178,290,000 after acquiring an additional 2,170,000 shares during the last quarter. Viking Global Investors LP increased its position in BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock worth $675,505,000 after acquiring an additional 1,488,552 shares during the period. Dimensional Fund Advisors LP increased its position in BioMarin Pharmaceutical by 48.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company's stock worth $197,405,000 after acquiring an additional 1,076,568 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in BioMarin Pharmaceutical by 3,494.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 957,011 shares of the biotechnology company's stock valued at $56,875,000 after purchasing an additional 930,390 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Up 3.8%

Shares of BioMarin Pharmaceutical stock opened at $63.81 on Friday. The firm has a market capitalization of $12.33 billion, a PE ratio of 172.46, a price-to-earnings-growth ratio of 0.49 and a beta of 0.24. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The company's fifty day moving average price is $58.19 and its two-hundred day moving average price is $57.06. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $66.28.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. The company had revenue of $989.71 million during the quarter, compared to analysts' expectations of $932.03 million. During the same quarter in the prior year, the company posted $1.44 EPS. The business's revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, analysts expect that BioMarin Pharmaceutical Inc. will post 4.22 EPS for the current year.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

Analysts Set New Price Targets

BMRN has been the subject of a number of research reports. Weiss Ratings raised shares of BioMarin Pharmaceutical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, June 26th. The Goldman Sachs Group initiated coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a "neutral" rating and a $69.00 price objective for the company. Sanford C. Bernstein reduced their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an "outperform" rating for the company in a research note on Tuesday, May 5th. UBS Group reissued a "neutral" rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, July 14th. Finally, Oppenheimer boosted their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an "outperform" rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $87.86.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source